Valiant Organics Share Price

Conference Call with Valiant Organics Management and Analysts on Q1FY24 Performance and Outlook. पूरी कमाई का ट्रांसक्रिप्ट सुनें.

• ट्रेंडलाइन
• 2 वर्ष 10 महीने पहले

Agrochemicals firm Valiant Organics announced Q1FY23 Result : INR 2,660 Mn Operational Revenue INR 319 Mn Operating EBITDA 11.99% Operating EBITDA Margin 6.35% PAT Margin INR 169 Mn Profit After Tax INR 5.52/ Share EPS Q1-FY23 financials were impacted primarily due to the unfortunate blast at our Chlorination plant in Sarigam leading to shutdown for an extensive period of time, as well as subdued demand of our hydrogenation products and mandatory maintenance shut down at one of our Ammonolysis plant. The Sarigram plant has resumed partial operations since 21st July 2022, although it will take a few weeks to restore to normalcy due to ordering/delivery/erection of new machinery. The cost of damage and loss of business is covered under insurance. With regard to PAP, batch process is running as planned and have maintained an average run rate of 350 MT/month for Q1-FY23. The Pharma Intermediates project is still awaiting approvals. Water runs have been done and trial runs and production in a phased manner will commence immediately once the approvals are received. Price volatility stabilized to a certain extent in Q1-FY23 for our key raw materials and the positive impact of this will be seen in the quarters ahead if the market dynamics continue to remain the same. परिणाम PDF

• ट्रेंडलाइन
• 3 वर्ष 10 महीने पहले

Agrochemicals firm Valiant Organics declares Q4FY22 result: INR 3,476 Mn Operational Revenue 16.40% Operating EBITDA Margin 10.67% PAT Margin INR 570 Mn Operating EBITDA INR 371 Mn Profit After Tax INR 11.12/ Share EPS Strong Revenue growth in Q4FY22 & Full Year FY22 on a YoY and QoQ basis owing to higher prices as well as volume addition on account of PAP ramp up Raw Material prices and market volatility continued to remain under pressure due to the geopolitical situations PAP ramp up continues to be on track and we have now achieved production of 300+ MT per month OAP & Pharma Intermediates projects both are on-track with no significant delays. OAP Phase 1 trial run has been successful and both OAP and Pharma Intermediates plant expected to commence production from Q2-FY23 Direct and deemed exports together accounted for 14% in Q4-FY22 and 16% in FY22 Result PDF

• ट्रेंडलाइन
• 4 साल पहले